The TAM Receptor Tyrosine Kinases Axl and Mer Drive the Maintenance of Highly Phagocytic Macrophages
Overview
Authors
Affiliations
Many apoptotic thymocytes are generated during the course of T cell selection in the thymus, yet the machinery through which these dead cells are recognized and phagocytically cleared is incompletely understood. We found that the TAM receptor tyrosine kinases Axl and Mer, which are co-expressed by a specialized set of phagocytic thymic macrophages, are essential components of this machinery. Mutant mice lacking Axl and Mer exhibited a marked accumulation of apoptotic cells during the time that autoreactive and nonreactive thymocytes normally die. Unexpectedly, these double mutants also displayed a profound deficit in the total number of highly phagocytic macrophages in the thymus, and concomitantly exhibited diminished expression of TIM-4, CD163, and other non-TAM phagocytic engulfment systems in the macrophages that remained. Importantly, these previously unrecognized deficits were not confined to the thymus, as they were also evident in the spleen and bone marrow. They had pleiotropic consequences for the double mutants, also previously unrecognized, which included dysregulation of hemoglobin turnover and iron metabolism leading to anemia.
Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us?.
Malikova I, Worth A, Aliyeva D, Khassenova M, Kriajevska M, Tulchinsky E Cell Death Dis. 2025; 16(1):155.
PMID: 40044635 PMC: 11883011. DOI: 10.1038/s41419-025-07480-9.
Parinot C, Chatagnon J, Rieu Q, Roux S, Neel D, Hamieh F Int J Mol Sci. 2024; 25(12).
PMID: 38928335 PMC: 11203748. DOI: 10.3390/ijms25126630.
Ghosh S, Finnemann S, Vollrath D, Rothlin C Int J Mol Sci. 2024; 25(10).
PMID: 38791338 PMC: 11121519. DOI: 10.3390/ijms25105299.
Jordan C, Tunbridge M, Husain I, Kitai H, Dilts M, Fay O JCI Insight. 2024; 9(5).
PMID: 38261406 PMC: 10972596. DOI: 10.1172/jci.insight.178502.
Novel Therapeutic Avenues for Hypertrophic Cardiomyopathy.
Patil D, Bhatt L Am J Cardiovasc Drugs. 2023; 23(6):623-640.
PMID: 37670168 DOI: 10.1007/s40256-023-00609-1.